Another important pharmacological target for anticancer therapy is EZH2, a component of the polycomb repressive complex, responsible for the silencing of tumor suppressor genes in cancer cells as well as a promoter of tumor angiogenesis via dowregulation of vasohibin 1 expression (VASH1), a soluble inhibitor of tumor angiogenesis [135,136]. Here, EZH2 is linked to neoplasm.